AbbVie Juvmo approved by FDA for Parkinson’s disease
AbbVie announced that the FDA has approved Juvmo (tavapadon) tablets to treat adults with Parkinson’s disease. The company says Juvmo is the first and only selective d1/d5 receptor agonist approved for this use and can be taken once daily with or without levodopa. According to the company, app
<p>AbbVie announced that the FDA has approved Juvmo (tavapadon) tablets to treat adults with Parkinson’s disease. The company says Juvmo is the first and only selective d1/d5 receptor agonist approved for this use and can be taken once daily with or without levodopa. According to the company, app</p>